Hematology, Transfusion and Cell Therapy最新文献

{"title":"RITUXIMAB WITH INVOLVED FIELD IRRADIATION FOR EARLY-STAGE DIFFUSE LARGE CELL LYMPHOMA","authors":"Vera Kovalskaya ,&nbsp;Natalya Falaleeva ,&nbsp;Stanislav Shklyaev ,&nbsp;Andrey Chelmakov ,&nbsp;Ludmila Grivtsova ,&nbsp;Marwa Abdelgawad ,&nbsp;Ahmed Mubarek","doi":"10.1016/j.htct.2025.103895","DOIUrl":"10.1016/j.htct.2025.103895","url":null,"abstract":"<div><h3>Objective</h3><div>Efficacy and safety of Involved Field (IF) radiotherapy in combination for anti-CD20 antibody Rituximab (MabThera) and Involved field Radiotherapy for early-stage Diffuse Large Cell lymphoma (DLBCL) in a prospective, single-arm multicenter study.</div></div><div><h3>Methodology</h3><div>Forty-five stage I–II FL patients received 8 cycles of Rituximab (375  mg/m²) and IF irradiation (30/40 Gy). Progression-Free Survival (PFS) 1-year from treatment start is the primary endpoint. Secondary endpoints were complete response rates, toxicity, quality of life with protocol defined visits up to month 15.</div></div><div><h3>Results</h3><div>For the primary endpoint, PFS at 1-year was 85% for the intention-to-treat set. Long-term data were captured in selected sites and evaluated as post hoc analysis in the Per Protocol (PP) set: PFS was 78% at 1-year with a median follow-up of 15 months, respectively. There were 17/45 recurrences in the PP set, of which 14 were outside the radiation volume only. There were 9 serious adverse events (3 related to the therapy) during the first 15 months.</div></div><div><h3>Conclusion</h3><div>IF radiotherapy combined with Rituximab is well tolerated and highly efficient with low rates of recurrence in the first years in early-stage DLBCL. The efficacy is comparable with more aggressive therapy approaches without compromising the quality of life and maintains for an extended follow-up of more than 3 years.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103895"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study","authors":"Ana Maria Meireles ,&nbsp;Rita Calisto ,&nbsp;Maria José Bento ,&nbsp;Pedro Martinho Gouveia ,&nbsp;Susana Bizarro ,&nbsp;Manuel Teixeira ,&nbsp;Cláudia Moreira ,&nbsp;Ana Espírito Santo ,&nbsp;Mário Mariz","doi":"10.1016/j.htct.2025.103935","DOIUrl":"10.1016/j.htct.2025.103935","url":null,"abstract":"<div><h3>Background</h3><div>The chronic myeloid leukaemia population, treatment patterns and responses in Portugal are unknown. The aim of this study is to describe these features in a Portuguese reference centre.</div></div><div><h3>Methods</h3><div>A retrospective cohort study included patients with chronic myeloid leukaemia, treated between 2012 and 2022 at the Instituto Português de Oncologia of Porto. Data were obtained from the Cancer Registry of the institution and clinical records. Variables included demographic data, treatments administered, responses (hematologic, cytogenetic, major and deep molecular responses), adverse events, and survival. Patients without available data, those treated in a clinical trial context, and those admitted only for hematopoietic transplantation were excluded.</div></div><div><h3>Results</h3><div>Ninety-nine patients were included in this study, with a median age of 52 years (range: 7–84 years) at diagnosis. The first-line treatment was imatinib in 96 patients however 33 required second-line with dasatinib, and 17 discontinued treatment while maintaining response. Regarding responses, 95 (96 %) patients achieved cytogenetic response, 90 (94 %) achieved major molecular response, and 71 (72 %) achieved deep molecular response. At three months, the early molecular response rate was 77 %. At 12 months of treatment, of the 67 patients with response evaluation, 93 % achieved complete cytogenetic response and 49 % major molecular response. Both imatinib and dasatinib were well tolerated. The median follow-up was eight years. The five-year overall survival was 96 %.</div></div><div><h3>Conclusion</h3><div>This study is the first to characterize chronic myeloid leukaemia patients at a Portuguese centre. The patient characteristics, responses, and overall survival were within the expected range according to the literature. This study confirms the good prognosis of chronic myeloid leukaemia and the good responses using imatinib as first-line treatment.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103935"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral post-surgical complications in patients with hemophilia and von Willebrand disease","authors":"Luisa Catarina Porfirio de Sousa,&nbsp;Elanne Cristina Garcia da Costa Félix,&nbsp;Wagner Hespanhol,&nbsp;Raquel dos Santos Pinheiro","doi":"10.1016/j.htct.2025.103936","DOIUrl":"10.1016/j.htct.2025.103936","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prevalence of post-surgical complications in patients with hemophilia and von Willebrand disease.</div></div><div><h3>Methods</h3><div>A prospective, cross-sectional study with descriptive and exploratory data analysis was conducted at the outpatient clinic of the Arthur de Siqueira Cavalcanti State Institute of Hematology (Hemorio). The sample included 26 patients who underwent tooth extraction following the protocols of the Brazilian Ministry of Health.</div></div><div><h3>Results</h3><div>The prevalence of post-surgical complications identified in the study was 26.07 %, with 15.38 % of cases presenting bleeding after extraction.</div></div><div><h3>Conclusion</h3><div>The prevalence of postoperative complications found in this study was notably higher in patients with von Willebrand disease, followed by those with severe hemophilia.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103936"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WHICH IS THE BEST TREATMENT FOR AML WITH RESTRICTED RESOURCES","authors":"Mipsang Lama","doi":"10.1016/j.htct.2025.103870","DOIUrl":"10.1016/j.htct.2025.103870","url":null,"abstract":"<div><div>AML itself is one of the worst prognostic hematological malignancies which has to be managed timely, adequately and aggressively to get on top of it. Such, kind of patients will need intensive chemotherapy therapy (3+7, Flag IDA) followed by allogeneic SCT. That is why it is challenging to manage such cases in resource limited setting. Due to constant development of new drugs treatment of such patients with azacytidine and venetoclax have been lot easier. With these drugs we are being able to put patients in remission with less toxicities, and low cost as compared to intensive chemotherapy.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103870"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A RARE CASE OF DIFFUSE LARGE B-CELL LYMPHOMA PRESENTING WITH CHRONIC GASTROINTESTINAL SYMPTOMS: A DIAGNOSTIC CHALLENGE","authors":"Bulut Sat ,&nbsp;Burak Demir ,&nbsp;Birol Güvenç","doi":"10.1016/j.htct.2025.103909","DOIUrl":"10.1016/j.htct.2025.103909","url":null,"abstract":"<div><div>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, but primary Gastrointestinal (GI) involvement remains relatively rare. Diagnosing GI lymphoma is challenging due to its nonspecific symptoms, such as chronic abdominal pain, weight loss, and anemia, which can mimic benign gastrointestinal disorders. This case highlights a patient with persistent GI symptoms who was ultimately diagnosed with DLBCL, underscoring the importance of considering lymphoma in cases of unexplained GI complaints and treatment-resistant anemia. A 45-year-old female presented with eight months of persistent epigastric pain, bloating, and indigestion. Despite undergoing multiple endoscopic and colonoscopic evaluations, no active pathology was identified. Due to persistent symptoms and treatment-resistant anemia, a bone marrow biopsy was performed, which was reported as normocellular. Over the next two months, she experienced unintentional weight loss of 25 kg raising suspicion for an underlying malignancy. FDG-PET/CT was performed, revealing diffuse thickening of the bowel wall in the left abdomen and periumbilical region, increased metabolic activity in mesenteric lymph nodes, mild bone marrow uptake, and abnormal activity in the anal canal. Given the concern for a lymphoproliferative disorder, the patient underwent diagnostic laparoscopy followed by excisional mesenteric biopsy, which confirmed Diffuse Large B-Cell Lymphoma (DLBCL) of non-germinal center B-cell phenotype. This case emphasizes the importance of recognizing lymphoma as part of the differential diagnosis in chronic gastrointestinal complaints, particularly when associated with unexplained anemia and significant weight loss despite normal endoscopic findings. It also underscores the critical role of PET/CT in identifying occult lymphoma and the necessity of excisional biopsy for definitive diagnosis in cases where conventional diagnostic methods fail to reveal a cause. Early recognition and diagnosis of GI-DLBCL are crucial for timely treatment and improved patient outcomes.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103909"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACUTE LYMPHOBLASTIC LEUKEMIA DIAGNOSED FOUR YEARS AFTER HSCT IN A BETA THALASSEMIA PATIENT: A CLINICAL CASE","authors":"Samira Hasanova,&nbsp;Huseyn Kerimov,&nbsp;Avesta Allahverdiyeva,&nbsp;Azer Kerimov,&nbsp;Nargiz Aliyeva,&nbsp;Seher İsmayilova","doi":"10.1016/j.htct.2025.103907","DOIUrl":"10.1016/j.htct.2025.103907","url":null,"abstract":"<div><h3>Introduction</h3><div>Beta thalassemia is an inherited blood disorder caused by defective synthesis of the beta chains of hemoglobin. This results in the production of ineffective red blood cells, leading to anemia and a severe reduction in the ability to transport oxygen to organs and tissues. In some cases, patients with beta thalassemia, due to prolonged treatment processes and other factors, may develop malignant hematologic disorders. This case presentation describes a patient diagnosed with beta thalassemia major who developed Acute Lymphoblastic Leukemia (ALL) four years after undergoing Hematopoietic Stem Cell Transplantation (HSCT).</div></div><div><h3>Materials and methods</h3><div>A patient diagnosed with beta thalassemia major, registered at the Thalassemia Center (TC), underwent allogeneic HSCT in 2020 and was later diagnosed with T-cell Acute Lymphocytic Leukemia (T-ALL) four years post-transplant.</div></div><div><h3>Results</h3><div>A 19-year-old male patient was diagnosed with beta thalassemia major at the age of one year. He has been under regular follow-up at the Thalassemia Center since the age of six. At seven years old, he was officially diagnosed with “Beta Thalassemia Major” (HbA2 ‒ 3.9%; HbF ‒ 57.1%) and has since been on a transfusion regimen with chelation therapy. On February 23, 2020, he underwent an allogeneic bone marrow transplantation from his HLA 10/10 matched sibling using the BU/Flu/CY/ATG/TT myeloablative conditioning regimen. Post-transplant chimerism analysis showed 93% donor cells. The patient was regularly monitored at the TC-HSCT outpatient clinic.</div></div><div><h3>Medical history</h3><div>The patient was born from his mother’s third pregnancy and third delivery.</div><div> <!-->• Two siblings from previous pregnancies did not survive.</div><div> <!-->• He was born at term with a birth weight of 3500g.</div><div> <!-->• He had incomplete routine vaccinations.</div><div> <!-->• He had a history of measles and chickenpox infections.</div><div> <!-->• The family denies a history of tuberculosis or venereal skin diseases.</div><div> <!-->• One healthy sibling lives at home.</div><div> <!-->• Parents are not consanguineous.</div><div> <!-->• The father was diagnosed with Hodgkin lymphoma two months ago and started treatment.</div><div>On November 5, 2024, the patient presented with extensive bruising and petechiae over his entire body. His general condition was severe, and laboratory findings were:</div><div> <!-->• Leukocytes (L): 284.32 × 10³/µL</div><div> <!-->• Hemoglobin (Hb): 121 g/L</div><div> <!-->• Platelets (Tr): 30 × 10⁹/L</div><div> <!-->• Blast cells: 80%</div><div>The patient was hospitalized and diagnosed with T-ALL.</div><div>Flow Cytometry Findings:</div><div> <!-->• SSC/CD45 analysis revealed 90% blast cells in the CD45 low region.</div><div> <!-->• Blast cells expressed T-lymphoid markers (CD2+, CD3+, CD5+, CD7+, CD38+).</div><div> <!-->• Based on clinical and laboratory findings","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103907"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UPDATES ON HODGKIN DISEASE","authors":"Valeh Huseynov","doi":"10.1016/j.htct.2025.103871","DOIUrl":"10.1016/j.htct.2025.103871","url":null,"abstract":"<div><div>Hodgkin Lymphoma (HL) is a B-cell malignancy accounting for approximately 10% of all lymphoma cases and 5% of lymphoma-related mortalities. Incidence increases in younger adults and those above 55-years of age and has a bimodal distribution. Approximately 95% of all HL cases are diagnosed as classical Hodgkin Lymphoma (cHL) and 5% as Nodular Lymphocyte Predominant B-cell Lymphoma (NLPBL). Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte‐rich HL are subgroups of classical HL. Risk Stratification An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by Positron Emission Tomography (PET) scan, are used to optimize therapy. Risk‐Adapted Therapy Initial therapy for HL patients is based on the histology of the disease, the anatomical stage and the presence of poor prognostic features. Patients with early‐stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved‐field radiation therapy, whereas those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. However, newer agents including brentuximab vedotin and anti‐PD‐1 antibodies are now standardly incorporated into frontline therapy. Management of Relapsed/Refractory Disease High‐Dose Chemotherapy (HDCT) followed by an Autologous Stem Cell Transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD‐1 blockade, non‐myeloablative allogeneic transplant or participation in a clinical trial should be considered. The AETHERA study (NCT01100502) shows that Brentuximab Vedotin (BV) improves Progression-Free Survival (PFS) after ASCT in patients with Refractory or Relapsed HL (R/R HL). For patients who relapse after ASCT, BV, and anti-PD-1, monoclonal antibodies were considered incurable, and their outcome is rather dismal, with a median Overall Survival (OS) of 2-years. For Refractory or Relapsed cHL (R/R cHL) patients who have failed both ASCT and BV, Chimeric Antigen Receptor T-cell (CAR-T) therapy offers a new therapeutic option.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103871"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translation, cross-cultural adaptation, and validation of the HCT frailty scale for hematopoietic stem cell transplant candidates: an observational study","authors":"Luz Lorca ,&nbsp;Barbara Puga Larrain ,&nbsp;Ivana Leao Ribeiro ,&nbsp;Ivana Gonzalez Valdivia ,&nbsp;Angelia Fernández Hermoso ,&nbsp;Francisca Bass Maturana ,&nbsp;Francisco Canelo Lazcano","doi":"10.1016/j.htct.2025.103933","DOIUrl":"10.1016/j.htct.2025.103933","url":null,"abstract":"<div><h3>Introduction</h3><div>Hematopoietic stem cell transplantation (HSCT) is a treatment option for patients with hematologic malignancies. The aim of this study is to validate the Hematopoietic Cell Transplantation Frailty Scale in a Chilean population.</div></div><div><h3>Methods</h3><div>This was a cross-sectional scale validation study. The sample consisted of patients with various hematologic malignancies who were transplantation candidates. The study had two stages: (1) translation (forward and backward) and (2) psychometric analysis, including face validity, test-retest reliability, and content validity. Descriptive analyses included mean, standard deviation, and the 95 % confidence interval. Reliability was assessed with Spearman's correlation, and content validity used Kendall's W test.</div></div><div><h3>Results</h3><div>Fifty-four patients (53.7 % women) were included, with multiple myeloma being the most frequent diagnosis (33.3 %). Positive and strong correlations were identified (Spearman's Rho [ρ]: 1.0; <em>p</em>-value &lt;0.001) for all items on the scale. Regarding content validity, there was agreement among evaluators for the categories of relevance and coherence (<em>p</em>-value &lt;0.01; Kendall's W range: 0.13–0.17) but not for “clarity” (<em>p</em>-value = 0.11; Kendall's W: 0.07). Some terms in the content were adjusted without affecting the overall structure of the scale. In the retest analysis, descriptive values were similar to the initial test.</div></div><div><h3>Conclusion</h3><div>The Spanish version of the Hematopoietic Cell Transplantation Frailty Scale for Chile is conceptually and linguistically equivalent to the original instrument. Additionally, it demonstrated adequate psychometric properties in terms of validity and reliability.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103933"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144763995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DYNAMIC BALANCE EVALUATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING CONSOLIDATION THERAPY","authors":"Fulya Ipek-Erdem ,&nbsp;Sena Sonkaya ,&nbsp;Arzu Genç ,&nbsp;Şebnem Yılmaz","doi":"10.1016/j.htct.2025.103883","DOIUrl":"10.1016/j.htct.2025.103883","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to clinically assess the dynamic balance performance in children with Acute Lymphoblastic Leukemia (ALL) undergoing consolidation therapy by comparing their performance with normative data, thereby identifying potential treatment-related impairments in this population.</div></div><div><h3>Methodology</h3><div>This descriptive study was conducted at Dokuz Eylül University, Faculty of Physiotherapy and Rehabilitation in Turkey. Fifteen children with ALL were enrolled and divided into the following age groups: 6–7 years (n = 8), 8–9 years (n = 4), 10–11 years (n = 1), 12–13 years (n = 1), and 14–15 years (n = 1). All participants underwent the Limit of Stability (LOS) test using a Balance Master NeuroCom system, which quantifies key parameters including Reaction Time (RT), Movement Velocity (MVL), Directional Control (DCL), Maximum Excursion (MXE), and Endpoint Excursion (EPE). Given the minimal sample sizes in the 10–11, 12–13, and 14–15 years groups, the primary analysis focused on the 6–7 and 8–9 years groups. Normative data for each parameter were extracted from previous studies using the Balance Master LOS test in healthy children.</div></div><div><h3>Results</h3><div>In the 6–7 years group, the average RT was 1.05 seconds (norm: 0.79s), and MVL was 4.31°/s (norm: 4.64°/s). In contrast, DCL was 62.25% (norm: 52.50%), MXE reached 88.0% (norm: 83.3%), and EPE was 66.5% (norm: 64.54%). In the 8–9 years group, the average RT was 1.06 seconds (norm: 0.82s), and MVL was 3.7°/s (norm: 5.42°/s), while DCL was elevated at 73.50% (norm: 60.20%). Both MXE (88.0%) and EPE (79.75%) in this group were comparable to their respective normative values (83.2% and 69.2%).</div></div><div><h3>Conclusion</h3><div>Our findings demonstrate that postural control is compromised in children with ALL undergoing consolidation therapy. Elevated sway speeds on firm surfaces suggest diminished balance performance, while the mixed results on foam conditions highlight difficulties with sensory integration. These preliminary observations underscore the need for targeted interventions and further research with larger samples to clarify the mechanisms behind these deficits.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103883"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LANDSCAPE OF SOMATIC MUTATIONS OF MYELOPROLIFERATIVE NEOPLASMS IN PAKISTANI PATIENTS","authors":"Mehreen Ali Khan","doi":"10.1016/j.htct.2025.103901","DOIUrl":"10.1016/j.htct.2025.103901","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;This study aimed to screen Myeloproliferative Neoplasm (MPN) patients for four known genetic mutations following their clinical and bone marrow examinations to establish a diagnosis before treatment.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This descriptive cross-sectional study was conducted at the Armed forces bone marrow transplant center, Rawalpindi, between January 2018 and January 2021. A total of 159 MPN patients who fulfilled inclusion criteria were enrolled. All patients underwent bone marrow biopsy after providing informed consent, history recording, and examination. Peripheral blood samples were screened for somatic mutations in JAK2 V617F, JAK2 exon 12, CALR, and cMPL genes. The JAK2 V617F and cMPL mutations were analyzed using conventional PCR, and the PCR products were analyzed on polyacrylamide gel electrophoresis. JAK2 Exon 12 and CALR mutations were analyzed using the fragment analysis technique. Positive and negative controls were run with each sample. The final results were analyzed using Gene Mapper 5 Software (Applied Biosystems). The gene scan data was interpreted by analyzing the electropherograms and the genotyping data sheet. The data were analyzed using the Statistical Package for Social Sciences (SPSS) version 25.0.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 159 MPN patients fulfilled the inclusion criteria, with 104 (65.4%) males and 55 (34.6%) females. The median age of patients was 54-years (IQR: 38‒64). Among Philadelphia negative (Ph-ive) MPN patients, 69 (43.4%) were diagnosed with Primary Myelofibrosis (PMF), 60 (37.7%) as Polycythemia Vera (PV), and 30 (18.9%) as Essential Thrombocytosis (ET). The frequency of the JAK2 V617F mutation in PV, ET, and PMF patients was 85%, 51.4%, and 34.5%, respectively. CALR mutation was observed only in 1 PMF and 5 (17.2%) ET patients. Additionally, cMPL mutation was not found among our patients. However, 14 (8.8%) patients were triple negative (negative for the JAK2 V617F, CALR, and cMPL mutations).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;PMF was the most frequent (43.4%) condition among Ph-ive MPN patients, followed by PV 60 (37.7%) and ET 30 (18.9%). The frequency of JAK2 V617F mutation in PV, ET, and PMF patients was 85%, 51.4%, and 34.5%, respectively. CALR mutation was observed only in 5 (17.2%) ET and 1 PMF patient. These five mutations are among the diagnostic criteria established by the World Health Organization, which enable a quick and reliable diagnosis of MPN.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;This study highlights the demographics, diagnosis, and mutations in four genes of MPN patients from a low-income country. PMF was the most frequent (43.4%) among Ph-ive MPN patients, followed by PV 60 (37.7%) and ET 30 (18.9%). The frequency of the JAK2 V617F mutation in PV, ET, and PMF patients was 85%, 51.4%, and 34.5%, respectively. CALR mutation was observed in only 1 PMF and 5 (17.2%) ET patients. These five mutations are among the diagn","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103901"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}